Advancing Canine Health: A New Era of Longevity for Our Best Friends
Significant Investment Boosts Canine Longevity Research
Loyal, a company dedicated to enhancing the healthy lifespan of dogs, recently announced the successful completion of its Series C funding round, securing an impressive $100 million. This latest investment elevates the total capital raised by the company to more than $250 million since its establishment in 2019. The funding round saw leadership from age1, the latest iteration of Laura Deming's Longevity Fund, with additional contributions from Baillie Gifford and existing investors.
CEO's Vision: Extending Healthy Lives for Dogs
Celine Halioua, founder and CEO of Loyal, articulated the company's core mission: to enable dogs to enjoy longer, healthier lives. She emphasized that the organization is nearing its objective of introducing an FDA-approved medication for canine lifespan extension. This recent influx of capital is crucial for navigating the remaining FDA requirements and facilitating the product's entry into the market.
Key Drug Candidate: LOY-002's Progress Towards Approval
The flagship product in Loyal's pipeline, LOY-002, is an oral medication designed for daily administration. Its purpose is to prolong the healthy years of older dogs by targeting metabolic processes associated with aging. Loyal has successfully completed the "Reasonable Expectation of Effectiveness" and "Target Animal Safety" technical sections, which are essential components for achieving FDA Expanded Conditional Approval. The final major regulatory hurdle is currently underway, with submission anticipated later this year.
Pioneering Clinical Trials in Veterinary Medicine
In a related development, Loyal confirmed the successful enrollment completion for its pivotal STAY study. This extensive clinical trial involves 1,300 dogs and is being conducted across 70 veterinary clinics throughout the nation. Loyal proudly states that the STAY study represents the largest clinical trial ever undertaken within the field of veterinary medicine, underscoring the scale and ambition of their research efforts.
Further Details on Loyal's Endeavors
For individuals interested in learning more about Loyal's pioneering work and the advancements in canine longevity, additional information is available directly on the company's official website.